HIV-associated lipodystrophy and excess visceral adiposity — evidence across compounds
Every compound the Institute assesses in hiv-associated lipodystrophy and excess visceral adiposity, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in hiv-associated lipodystrophy and excess visceral adiposity, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| TesamorelinGrowth-hormone-releasing hormone analogue | Visceral adipose tissue reduced by 15.2 % versus 5.0 % increase with placebo at 26 weeks | estimated difference −20.2 % (95 % CI −25.7 to −14.7) | Moderate | 2 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Tesamorelin in hiv-associated lipodystrophy and excess visceral adiposity: effect on the anchor outcome — Moderate
- Tesamorelin in hiv-associated lipodystrophy and excess visceral adiposity: tolerability and discontinuation — Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375 · PMID 18052660
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12(2):139–157. doi:10.2165/00063030-199912020-00007 · PMID 18031173
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.